Description: Through a NIDA grant, assessment of system performance will be studied. Buy-in by stakeholders (patients, clinicians and managers) was the initial focus of this process. Five specific aims (quality, productivity, satisfaction, financial performance and risk management) with nine related hypotheses were chosen for study based on needs assessment meetings with stakeholders and literature review. The final selection of an electronic information system is informed by specific criteria, including ability to provide relevant data regarding aims mentioned above, information obtained from stakeholders and literature review, and determination as to whether the system will be developed totally in-house, by an outside vendor or as a hybrid. Presentations by vendors were evaluated using specific criteria.
Lessons Learned: A detailed survey of 105 clinician stakeholders was done to determine (1) ability to use the current paper-electronic system; (2) challenges encountered with the current system; and, (3) training needs.
Recommendations: Results of this detailed program description have potential to inform continuing discussions about selection and impact of integrated electronic systems in enhancing healthcare outcomes and agency cost-effectiveness in substance abuse treatment settings for this unique patient population.
Learning Objectives:
Identify the challenges to selecting an electronic information system covering substance abuse treatment, primary medical care and social services.
Evaluate an electronic information system in the domains of quality, productivity, satisfaction, financial performance and risk management.
Apply the results of a clinician stakeholder survey to the process of implementing an electronic information system.
Keywords: Information Systems, Technology
Qualified on the content I am responsible for because: I was a co-author of the research study and am the study Project Coordinator.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Alcohol, Tobacco, and Other Drugs
![[ Visit Client Website ]](images/banner.gif)